Boosting the heart’s natural countermeasures against poor function is one way to treat heart failure, but existing therapies need to be given frequently. An antibody with enduring effects could ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

In 2023, the FDA approved the Miebo (perfluorohexyloctane ophthalmic solution), an eyedrop that helps prevent tear evaporation. Also available in 2024 is a treatment known as Lacrifill. It is injected ...

The debt refinancing is expected to help the company in the impending spinoff of its eye-care company, Bausch + Lomb. This drugmaker is expected to post quarterly earnings of $1.05 per share in ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is exploring a potential sale and is seeing interest from private equity ...

Bausch & Lomb (NYSE:BLCO) rose 9% after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International ...

Separate from the refinancing option, Bausch + Lomb is exploring a sale of itself, which could draw interest from private equity buyers. Wed, 18 Sep, 2024 - 10:13 Bausch Health is working with ...

Bausch + Lomb was put up for sale after a planned separation ... from sales of contact lenses and dry eye drugs Xiidra and Miebo. The company also sells surgical equipment to ophthalmologists.

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, ...